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Clinical investigators are listed in the [Appendix](#cam4888-app-0001){ref-type="app"}

**Clinical Trial Registration:** EMR 062202‐537.

Introduction {#cam4888-sec-0001}
============

Based on results from phase II and III trials [1](#cam4888-bib-0001){ref-type="ref"}, [2](#cam4888-bib-0002){ref-type="ref"}, [3](#cam4888-bib-0003){ref-type="ref"}, [4](#cam4888-bib-0004){ref-type="ref"}, [5](#cam4888-bib-0005){ref-type="ref"}, and a pooled analysis [6](#cam4888-bib-0006){ref-type="ref"}, cetuximab is recommended in combination with standard first‐line treatment regimens for patients with RAS wild‐type metastatic colorectal cancer (mCRC) [7](#cam4888-bib-0007){ref-type="ref"}, [8](#cam4888-bib-0008){ref-type="ref"}. The efficacy of cetuximab combination therapy is positively correlated with severe skin reactions. Although these reactions do not appear to influence global health status (GHS), overall quality of life (QoL), or social functioning [9](#cam4888-bib-0009){ref-type="ref"}, they do adversely affect skin‐related QoL measured with the DLQI [10](#cam4888-bib-0010){ref-type="ref"}, and have a negative impact on therapy compliance [9](#cam4888-bib-0009){ref-type="ref"}, [11](#cam4888-bib-0011){ref-type="ref"}, [12](#cam4888-bib-0012){ref-type="ref"}. QoL is unquestionably a clinically relevant outcome; however, it is rarely measured in routine practice. Data from randomized trials of cetuximab show that effective monitoring and management of skin reactions improves QoL and treatment compliance. No data are available from real‐world settings.

The ObservEr study (noninterventional, observational, multicenter, prospective study of QoL, safety, and efficacy of first‐line chemotherapy in combination with cetuximab) is the first observational study of first‐line cetuximab combined with standard chemotherapy in Italian patients with wild‐type *KRAS* mCRC tumors. This study provides an overview of QoL, the incidence of serious skin reactions, and efficacy with cetuximab in the first‐line setting.

Patients and Methods {#cam4888-sec-0002}
====================

The ObservEr study had competitive enrollment at 28 Italian centers (May 2011 through November 2012) of patients with *KRAS*‐wild‐type mCRC planning to receive first‐line treatment with cetuximab plus chemotherapy. The mCRC indication for cetuximab changed from *KRAS* to *RAS* wild type in December 2013, after enrollment had been completed [13](#cam4888-bib-0013){ref-type="ref"}. The protocol was approved by the independent ethics committee at each participating center and complied with International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws on observational studies. All patients provided written informed consent.

Patients {#cam4888-sec-0003}
--------

Main inclusion criteria were as follows: age ≥ 18 years; eligible to receive treatment with cetuximab plus chemotherapy (i.e., Eastern Cooperative Oncology Group performance status 0 or 1; [8](#cam4888-bib-0008){ref-type="ref"}); histologically proven and measurable (RECIST v1.1) metastatic adenocarcinoma of the colon or rectum; chemonaïve for metastatic disease; *KRAS* exon 2 wild‐type tumors; and planned cetuximab treatment according to the SmPC. Patients with prior investigational drug/agent/procedures were excluded. In each center, all consecutive eligible patients were prospectively enrolled in the study.

Treatment {#cam4888-sec-0004}
---------

Cetuximab was administered weekly in association with chemotherapy. Patients were treated until disease progression or unacceptable toxicity, according to clinical practice at the center. Treatment compliance (%) was calculated as total doses received / total planned doses × 100. Before starting therapy, investigators defined how they would manage skin toxicity in each patient, selecting one of the three skin protocols: (1) prophylactic, (2) reactive, or (3) according to usual clinical practice at their center [14](#cam4888-bib-0014){ref-type="ref"}. Skin Protocol 1 was started 1 day before the first cetuximab dose and consisted of topical vitamin K1 (Vigorskin©, MERCK Serono S.p.A, Rome, Italy) for ≥ 8 weeks. Skin Protocol 2, for managing grade 2--4 emergent skin toxicity, consisted of topical vitamin K1 applied as in Protocol 1 combined with doxycycline 100 mg per os twice daily.

Endpoints and measurement {#cam4888-sec-0005}
-------------------------

The primary endpoint was QoL. Cetuximab‐related skin reactions generally develop within the first 3 weeks of therapy [12](#cam4888-bib-0012){ref-type="ref"}, thus measuring QoL within the first 8--12 weeks of therapy allowed assessment of the impact of skin reactions. Patient‐reported outcomes were evaluated in all treated patients who had completed the baseline assessment and at least one postbaseline assessment that included completing the DLQI [15](#cam4888-bib-0015){ref-type="ref"} and EORTC Quality of Life Questionnaire (QLQ) C30 version 3.0 (EORTC DataCenter, Brussels). Patients completed the DLQI questionnaire at baseline and weekly during the first 8 weeks, then at every evaluation visit scheduled per local clinical practice until disease progression. EORTC QLQ‐C30 questionnaires were completed at baseline, first postbaseline evaluation (week: 8--12), and every subsequent evaluation visit.

Secondary endpoints were as follows: efficacy of the different skin management protocols assessed with the DLQI; incidence of cetuximab‐related skin toxicity and any serious AE (SAE); median overall survival (OS) and proportion of patients still alive at 2 years; progression‐free survival (PFS); overall response rate (ORR); metastases resection rate (mRR); and time required to receive *KRAS* laboratory test results. AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. OS was defined as months from first cetuximab dose to death or last contact when a death has not been registered; PFS was calculated as the time from start of therapy to evidence of clinical/radiologic progression. ORR was defined as the sum of complete responses (CR) and partial responses (PR). Both PFS and ORR were evaluated using RECIST v1.1 (Revised RECIST guideline (version 1.1). EJC 2009;45:228‐47). Radiologic assessment was per local clinical practice (every 8--12 weeks). Absence of a scheduled per protocol time (observational study) represents a potential source of bias for PFS and ORR. Time to *KRAS* test results were calculated as days between date of request and date of results.

Statistical analysis {#cam4888-sec-0006}
--------------------

Descriptive summary statistics for continuous variables comprised number of nonmissing observations, mean, standard deviation (SD), median, lower and upper quartile, minimum, and maximum, where appropriate. Frequencies and percentages were provided for categorical variables. DLQI and EORTC QLQ‐C30 results according to skin protocol chosen at baseline were evaluated by both *t*‐tests and an ANCOVA model, while changes in total score from baseline to first postbaseline visit according to predictors (age: ≥75 years, primary tumor surgery at baseline, \>1 metastatic site, irinotecan combination, best response in first‐line, skin toxicity in the first 8 weeks) were evaluated with an ANOVA model. The incidence of cetuximab‐related skin reactions according to age, chemotherapy (oxaliplatin vs. irinotecan), and gender were calculated with a multiple Poisson regression test. *P*‐values are reported and statistical significance declared for *P *\<* *0.05, without correction for multiplicity. OS and PFS were analyzed using the Kaplan--Meier method. An exploratory landmark analysis of OS was conducted in subgroups defined by skin toxicity (any grade vs. no skin toxicity).

Sample size required to evaluate QoL was 210 patients, based on: ☐The SD for changes in DLQI scores is approximately 7 units; [16](#cam4888-bib-0016){ref-type="ref"} thus, if 80% of the 210 patients scheduled for enrollment (*n *=* *167) were evaluable for the analysis of change in DLQI scores from baseline, then the distance from the boundaries of the two‐sided 95% confidence interval (CI) to the point estimate would be 1.07 units.☐DLQI total scores ranging from 0 to 1 were interpreted as no effect on dermatology‐related QoL, from 2 to 5 as a small effect, 6 to 10 as a moderate effect, 11 to 20 as a very large effect, and 21 to 30 as an extremely large effect [15](#cam4888-bib-0015){ref-type="ref"}.

☐The SD for changes in EORTC QLQ‐C30 GHS score is approximately 25 units; [17](#cam4888-bib-0017){ref-type="ref"} thus, if 80% of the 210 patients scheduled for enrollment (*n *=* *167) were evaluable for the analysis of change in EORTC QLQ‐C30 GHS from baseline to week 8, then the distance from the boundaries of the two‐sided 95% CI to the point estimate would be 3.82 units.☐A 10‐unit difference in the change in scores was considered clinically important [18](#cam4888-bib-0018){ref-type="ref"}, [19](#cam4888-bib-0019){ref-type="ref"}.

Results {#cam4888-sec-0007}
=======

Between May 2011 and November 2012, 228 patients were enrolled at 28 Italian centers; 225 were evaluable for safety analysis (Fig. [1](#cam4888-fig-0001){ref-type="fig"}). All patients in the safety population completed the study per protocol. Median age was 65 years. Demographic characteristics are summarized in Table [1](#cam4888-tbl-0001){ref-type="table-wrap"}.

![Patient disposition in the ObservEr Study.](CAM4-5-3272-g001){#cam4888-fig-0001}

###### 

Demographic and baseline characteristics of the safety population (*N* = 225)

  Characteristic                                       Patients
  ---------------------------------------------------- ----------------
  Age, years, median (range)                           64.76 (39--81)
  Age (class) *n* (%)                                  
  \<70 years                                           141 (62.2)
  ≥70 years                                            84 (37.3)
  Gender, *n* (%)                                      
  Male                                                 149 (66.2)
  Female                                               76 (33.8)
  Body surface area, m^2^, mean (SD)                   1.78 (0.192)
  Ethnicity, *n* (%)                                   
  White                                                223 (99.1)
  Asian                                                1 (0.4)
  Other                                                1 (0.4)
  ECOG performance status, *n* (%)                     
  0                                                    175 (76.8)
  1                                                    50 (23.2)
  Any disease, MedDRA SOC v.15, *n* (%)                118 (52.4)
  Primary tumor site, *n* (%)                          
  Colon/upper rectum                                   154 (68.4)
  Median/lower rectum                                  71 (31.6)
  Primary tumor surgery, *n* (%)                       162 (72.0)
  Patients with prior adjuvant chemotherapy, *n* (%)   80 (35.6)
  Number of metastatic sites, *n* (%)                  
  1                                                    141 (62.7)
  \>1                                                  84 (37.3)
  Site of metastasis, *n* (%)                          
  Liver                                                158 (70.2)
  Only liver                                           97 (43.1)
  Lung                                                 53 (23.6)
  Bone                                                 4 (1.8)
  Lymph node                                           64 (28.4)
  Other                                                51 (22.7)

John Wiley & Sons, Ltd

All 225 patients received cetuximab plus chemotherapy (Table [2](#cam4888-tbl-0002){ref-type="table-wrap"}), which was irinotecan‐based in 145 (64%), oxaliplatin‐based in 67 (30%), and other fluoropyrimidine‐based in 13 (6%). At baseline, prophylactic skin management (Protocol 1) was chosen for 160 patients (71.1%), reactive management (Protocol 2) was followed in 37 (16.4%), and a local institutional protocol (Protocol 3) was applied in the remaining 28 (12.4%). Compliance was 97.75% for the total population at week 8: compliance was ≥90% in 208 patients (92.4%), 70--89% in 15 (6.7%), and ≤69% in two (0.9%). After week 8, compliance was 96.8% for the 168 assessable patients. There was no difference in compliance between patients receiving irinotecan or oxaliplatin‐based chemotherapy. Compliance was lower when the chemotherapy combination backbone was capecitabine instead of 5FU (*P* \< 0.001).

###### 

Chemotherapy adopted in first and in second line in the safety population (*n* = 225)

  Chemotherapy                               Patients, *N* (%)
  ------------------------------------------ -------------------
  First line in combination with cetuximab   
  Irinotecan based                           145 (64.4)
  Oxaliplatin based                          67 (29.8)
  Other fluoropyrimidine based               13 (5.8)
  Second line                                119 (53.1)
  Anti‐VEGF based                            36 (31.2)
  Oxaliplatin based                          30 (25.2)
  Irinotecan based                           25 (21.0)
  Fluoropyrimidine monotherapy               14 (11.8)
  Anti‐EGFR based                            9 (7.6)
  Others                                     5 (4.2)

John Wiley & Sons, Ltd

Median duration of cetuximab therapy, calculated as time between first dose and end of treatment, was 22.0 weeks (interquartile range: 10--36 weeks). Main reasons for treatment discontinuation were as follows: progression (45.8%), clinical deterioration without documented progression (10.2%), treatment toxicity (any grade, 8.4%), resection (7.1%), and death (4.9%). No cetuximab‐related deaths were reported. All enrolled patients had *KRAS* wild‐type mCRC. Mean time from *KRAS* test request to *KRAS* status determination was 13.53 days (SD = 13.1), median 10 days (range: 0--91).

Quality of life {#cam4888-sec-0008}
---------------

DLQI questionnaire results for both baseline and postbaseline assessments were available for 169 patients overall, as well as separately for skin management Protocols 1 and 2. The overall mean total DLQI score was 0.29 at baseline, and increased to 2.79 at the first postbaseline visit (mean change from baseline 2.50; SD = 4.138), which corresponds to a "small effect" (2--5 points) [15](#cam4888-bib-0015){ref-type="ref"}, [17](#cam4888-bib-0017){ref-type="ref"}. The mean values for each individual question ranged from 0 to 1, which corresponds to "no effect on dermatology‐related QoL" [15](#cam4888-bib-0015){ref-type="ref"}, [17](#cam4888-bib-0017){ref-type="ref"}. Figure [2](#cam4888-fig-0002){ref-type="fig"}A presents total scores on the EORTC QLQ‐C30 QoL questionnaire (*n *=* *158). A decrease in mean values was observed for all functional scales, including GHS/QoL (Fig. [2](#cam4888-fig-0002){ref-type="fig"}B), indicating slight worsening [18](#cam4888-bib-0018){ref-type="ref"} during first‐line chemotherapy combined with cetuximab (*n *=* *161, first postbaseline evaluation; *n *=* *41 second postbaseline evaluation). No significant changes from baseline were recorded for individual symptoms (Fig. [2](#cam4888-fig-0002){ref-type="fig"}C; *n *=* *161, first postbaseline evaluation; *n *=* *41 second postbaseline evaluation).

![Results from EORTC QLQ‐C30 questionnaire for patients in the safety population with baseline and postbaseline assessments. (A) Association between total score at baseline and first postbaseline visit; dotted line indicates regression (*n *=* *158). (B) Mean change from baseline in Global Health Status and Function at first postbaseline visit (8--12 weeks---light blue; *n *=* *161) and at second postbaseline visit (20--24 weeks---dark blue; *n *=* *41). (C) Mean change from baseline for individual symptoms at first postbaseline visit (8--12 weeks---light blue; *n *=* *161) and to second postbaseline visit (20--24 weeks---dark blue; *n *=* *41); SD, standard deviation.](CAM4-5-3272-g002){#cam4888-fig-0002}

Secondary endpoints {#cam4888-sec-0009}
-------------------

Regarding the comparison between prophylactic and reactive skin management protocols, overall, the increase in DLQI score from baseline, and therefore a deterioration in QoL, was greater for patients receiving reactive compared to prophylactic treatment, but this was not significant (*P *=* *0.42). The only statistically significant difference was for the question "how itchy, sore, painful, or stinging has your skin been during the last week" (*P* = 0.0491). Again, reactive‐treated patients had a more impaired QoL than prophylactic‐treated patients, favoring the prophylactic skin management protocol (Table [3](#cam4888-tbl-0003){ref-type="table-wrap"}). The ANCOVA model confirmed the same trend for each item on the EORTC QLQ‐C30 (all *P *\>* *0.05).

###### 

Least square means of changes from baseline in the total DLQI score and the individual questions according to skin toxicity management protocols (safety set, *N* = 225)

  Over the last week:                                                                                                         Least square mean (95% CI)   *P*‐value (ANCOVA model)   
  --------------------------------------------------------------------------------------------------------------------------- ---------------------------- -------------------------- --------
  How itchy, sore, painful, or stinging has your skin been?                                                                   0.51 (0.37, 0.65)            0.83 (0.54, 1.11)          0.0491
  How embarrassed or self‐conscious have you been because of your skin?                                                       0.33 (0.21, 0.45)            0.52 (0.28, 0.76)          0.1663
  How much has your skin interfered with you going shopping or looking after your home or garden?                             0.23 (0.13, 0.33)            0.23 (0.03, 0.43)          0.9849
  How much has your skin influenced the clothes you wear?                                                                     0.16 (0.07, 0.25)            0.26 (0.06, 0.45)          0.3703
  How much has your skin affected any social or leisure activities?                                                           0.18 (0.09, 0.27)            0.21 (0.02, 0.39)          0.7675
  How much has your skin made it difficult for you to do any sport?                                                           0.13 (0.05, 0.21)            0.06 (−0.1, 0.22)          0.4586
  Has your skin prevented you from working or studying?                                                                       0.11 (0.01, 0.21)            −0.02 (−0.23, 0.18)        0.2687
  If no, over the last week, how much has your skin been a problem at work or studying?                                       0.1 (0.04, 0.17)             0.24 (0.11, 0.38)          0.0708
  How much has your skin created problems with your partner or any of your close friends or relatives?                        0.18 (0.09, 0.27)            0.2 (0.02, 0.38)           0.8708
  How much has your skin caused any sexual difficulties?                                                                      0.18 (0.08, 0.28)            0.17 (−0.03, 0.38)         0.9723
  How much of a problem has the treatment for your skin been, for example, by making your home messy, or by taking up time?   0.16 (0.07, 0.24)            0.34 (0.16, 0.52)          0.065
  Total score                                                                                                                 2.34 (1.56, 3.11)            3.05 (1.48, 4.62)          0.4217

SD, standard deviation; DLQI, Dermatology Life Quality Index; CI, confidence interval.

John Wiley & Sons, Ltd

Evaluating the EORTC QLQ‐C30 data with the ANOVA model revealed significant correlations between aspects of QoL and in particular previous primary tumor resection (Table [4](#cam4888-tbl-0004){ref-type="table-wrap"}), while there were no significant relationships between DLQI total score and predictors. Age did not affect any of the QoL items. AEs considered to be related to skin reactions were experienced by 176 patients (78.2%). There was no grade 4/5 skin AEs. Grade 3 AEs related to skin reactions occurred in 32 patients (14.2%). Significant relationships were found between the incidence of skin reactions and receiving an oxaliplatin combination (*P* \< 0.0001) or male gender (*P* = 0.0008) (Table [5](#cam4888-tbl-0005){ref-type="table-wrap"}).

###### 

Score change from baseline to first postbaseline visit on the EORTC QLQ‐C30 (*N* = 161)

                                             Global health status   Role functioning   Dyspnea   Diarrhea                       
  ------------------------------------------ ---------------------- ------------------ --------- ---------- ------ ------ ----- ------
  Predictors                                 Yes                    No                 Yes       No         Yes    No     Yes   No
  Age ≥ 75 years                             −5.8                   −4.8               −0.7      −3.3       4.4    2.5    4.4   3.2
  *P*                                        0.828                  0.669              0.687     0.848                          
  Primary tumor surgery at baseline          −9.3                   −1.3               −7.1      3.1        3.06   3.9    10    −2.3
  *P*                                        0.049                  0.047              0.838     0.021                          
  More than one metastatic site              −3.3                   −7.3               1.8       −5.8       3.15   3.8    3.3   4.4
  *P*                                        *P* = 0.252            0.087              0.852     0.808                          
  Irinotecan combination                     −6.3                   −4.3               −3.1      −0.9       7.22   −0.3   3.6   4.0
  *P*                                        0.565                  0.620              0.040     0.923                          
  Best response at first line                −3.8                   −6.8               −1.2      −2.8       5.17   1.8    1.5   6.1
  *P*                                        0.4                    0.705              0.341     0.307                          
  Skin toxicity event in the first 8 weeks   −3.96                  −6.63              −0.3      −3.7       1.9    5.1    1.5   6.2
  *P*                                        0.54                   0.533              0.467     0.410                          
  Overall model evaluation, *P*              0.268                  0.188              0.493     0.259                          

John Wiley & Sons, Ltd

###### 

Multivariate analysis of the incidence of cetuximab‐related skin reactions according to age, first‐line chemotherapy, and gender

  Predictors                   Incidence rate \[×1000\] (*N* = 212)   IRR (*N* = 212)     *P*
  ---------------------------- -------------------------------------- ------------------- ----------
  Age                                                                                     
  75+                          23.47                                                      
  60−75                        16.78                                  0.78 (0.61, 1)      0.0516
  60                           22.79                                  1.06 (0.83, 1.36)   0.6377
  Chemotherapy in first line                                                              
  Irinotecan                   16.3                                   1.72 (1.45, 2.04)   \<0.0001
  Oxaliplatin                  26.98                                                      
  Gender                                                                                  
  Female                       16                                     1.38 (1.14, 1.66)   0.0008
  Male                         21.85                                                      

IRR (Incidence rate ratio) and respective *P*−value are estimated by multivariate Poisson regression.

John Wiley & Sons, Ltd

Deaths during the study (*n* = 127) were attributed to tumors in 114 patients (90%). SAEs occurred in 53 patients (23.6%), mostly grade ≥3 (*n* = 45); the most common were intestinal obstruction (*n *=* *9); diarrhea (*n *=* *8); general physical health deterioration (*n *=* *5); hyponatremia, abdominal pain, and renal failure (*n *=* *3 each). In 12 patients (5.3%), the SAE resulted in death. A causal relationship with cetuximab was assessed for 12 patients (5.3%) with SAEs of grade 1--4. No cetuximab‐related deaths were recorded.

ORR was evaluated in 199 patients; no assessment of the best overall response was made for 26 (11.6%). Thirty‐one achieved a CR (13.8%) and 75 a PR (33.3%); 58 patients (25.8%) had stable disease; and 35 (15.6%) had progressive disease. The ORR (CR + PR) was 47.1%, and clinical benefit was 72.9%. In 45 patients (20.0%), ≥1 postbaseline surgical metastasis resection was reported, mainly from the liver (*n *=* *35). Median PFS was 8.3 months (95% CI: 6.70--9.40). After first‐line chemotherapy plus cetuximab, 119 patients (53.1% ‐ safety set) received second‐line chemotherapy. Considering only patients in progression of disease (*n* = 198), 109 patients (58, 1%) were treated with a second‐line chemotherapy.

Median OS calculated for 225 patients was 23.6 months (95% CI: 20.47--27.27); \~50% of patients were still alive at 24 months. An exploratory landmark analysis of OS in subgroups defined by skin toxicity (any grade vs. no skin toxicity) showed a significant correlation between skin reaction events and superior overall survival (*P *=* *0.0163) (Fig. [3](#cam4888-fig-0003){ref-type="fig"}).

![Overall survival by cetuximab‐related skin reaction (*N* = 225).](CAM4-5-3272-g003){#cam4888-fig-0003}

Discussion {#cam4888-sec-0010}
==========

Cetuximab plus chemotherapy is standard first‐line treatment for *RAS* wild‐type mCRC [3](#cam4888-bib-0003){ref-type="ref"}, [8](#cam4888-bib-0008){ref-type="ref"}. However, the impact of cetuximab‐related skin reactions on patient QoL in routine practice first‐line setting have not been reported to date. To address this, we enrolled an unselected population in which about 40% of patients were over age 70 and more than half had comorbidities. The mean *KRAS* test turnaround time was within the 14‐day limit stipulated in the Italian guidelines [20](#cam4888-bib-0020){ref-type="ref"}. In first line irinotecan was administered more frequently than oxaliplatin in combination with cetuximab, both combinations were safe and did not affect compliance.

Results with the DLQI and EORTC QLQ‐C30 questionnaires suggest that cetuximab plus chemotherapy does not have a negative impact on QoL in patients treated in routine practice with first‐line therapy for mCRC, supporting the results from the controlled CRYSTAL trial [9](#cam4888-bib-0009){ref-type="ref"}. We sought predictors of lower QoL through multivariate analysis and, while skin reactions were not significant, other factors were correlated with lower QoL in this setting. Of interest previous surgery for primary tumors at baseline predicted reduced QoL in terms of GHS, Role Functioning and Diarrhea on the EORTC QLQ‐C30 (Table [4](#cam4888-tbl-0004){ref-type="table-wrap"}), suggesting that patients would benefit from better supportive care in daily practice, to limit uneasiness and discomfort after primary tumor resection.

Both prophylactic and reactive skin management protocols produced similar favorable QoL outcomes, suggesting that careful management of skin toxicity with either of these protocols can limit the negative impact of this side‐effect on QoL in routine clinical practice and favor treatment compliance. The small number of patients using Skin Protocol 3 precluded analysis of outcomes.

Although no differences were found between the two protocols, the ObservEr investigators preferred the prophylactic protocol, because the patients found the added attention reassuring.

We observed the same correlation between OS and skin reactions that was reported in controlled clinical trials, and here too these adverse events were associated positively with efficacy. Discussing this correlation with patients should be considered when providing psychological support during therapy [21](#cam4888-bib-0021){ref-type="ref"}. Regarding efficacy, the median OS of 24 months is in line with findings from randomized trials in first‐line in patients with *KRAS* wild‐type tumors [1](#cam4888-bib-0001){ref-type="ref"}, [2](#cam4888-bib-0002){ref-type="ref"}, as were ORR, mRR, and PFS, the limitations of an observational study notwithstanding. Only about half of patients were amenable to second‐line therapy, indicating that in routine practice first line therapy is the most important component of an mCRC strategy [22](#cam4888-bib-0022){ref-type="ref"}, [23](#cam4888-bib-0023){ref-type="ref"}.

In the safety analysis, only 14% of patients experienced a grade ≥3 skin reaction and there were no cetuximab‐related deaths. These reporting frequencies suggest a good safety profile for cetuximab [1](#cam4888-bib-0001){ref-type="ref"}, [4](#cam4888-bib-0004){ref-type="ref"}, [5](#cam4888-bib-0005){ref-type="ref"}, despite the likelihood that unselected patients in an observational study tend to be in poorer general condition and to have lower tolerance for treatment than those selected for clinical trials.

In conclusion, in this observational experience chemotherapy plus cetuximab achieved the same effectiveness seen in randomized trials [1](#cam4888-bib-0001){ref-type="ref"}, [2](#cam4888-bib-0002){ref-type="ref"}, [5](#cam4888-bib-0005){ref-type="ref"}. The availability of management recommendations [14](#cam4888-bib-0014){ref-type="ref"} improved safety of cetuximab with limited severe skin‐related AEs and preserved compliance with treatment. The ObservEr study demonstrates that cetuximab‐based therapy in an unselected "real world" population can be effective without having a negative impact on QoL. We observed the same correlation between OS and skin reactions that was reported in controlled clinical trials, and here too these adverse events were associated positively with efficacy [24](#cam4888-bib-0024){ref-type="ref"}, [25](#cam4888-bib-0025){ref-type="ref"}, [26](#cam4888-bib-0026){ref-type="ref"}, [27](#cam4888-bib-0027){ref-type="ref"}.
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